Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

399 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of anthelmintic treatment during pregnancy on HIV plasma viral load: results from a randomized, double-blind, placebo-controlled trial in Uganda.
Webb EL, Kyosiimire-Lugemwa J, Kizito D, Nkurunziza P, Lule S, Muhangi L, Muwanga M, Kaleebu P, Elliott AM. Webb EL, et al. Among authors: kaleebu p. J Acquir Immune Defic Syndr. 2012 Jul 1;60(3):307-13. doi: 10.1097/QAI.0b013e3182511e42. J Acquir Immune Defic Syndr. 2012. PMID: 22728750 Free PMC article. Clinical Trial.
Evolution of drug resistance during 48 weeks of zidovudine/lamivudine/tenofovir in the absence of real-time viral load monitoring.
Lyagoba F, Dunn DT, Pillay D, Kityo C, Robertson V, Tugume S, Hakim J, Munderi P, Chirara M, Ndembi N, Goodall RL, Yirrell DL, Burke A, Gilks CF, Kaleebu P; DART Virology and Trial Team. Lyagoba F, et al. Among authors: kaleebu p. J Acquir Immune Defic Syndr. 2010 Oct;55(2):277-83. doi: 10.1097/QAI.0b013e3181ea0df8. J Acquir Immune Defic Syndr. 2010. PMID: 20686411
Pregnancy and infant outcomes among HIV-infected women taking long-term ART with and without tenofovir in the DART trial.
Gibb DM, Kizito H, Russell EC, Chidziva E, Zalwango E, Nalumenya R, Spyer M, Tumukunde D, Nathoo K, Munderi P, Kyomugisha H, Hakim J, Grosskurth H, Gilks CF, Walker AS, Musoke P; DART trial team. Gibb DM, et al. PLoS Med. 2012;9(5):e1001217. doi: 10.1371/journal.pmed.1001217. Epub 2012 May 15. PLoS Med. 2012. PMID: 22615543 Free PMC article. Clinical Trial.
Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA).
Gilks CF, Walker AS, Dunn DT, Gibb DM, Kikaire B, Reid A, Musana H, Mambule I, Kasirye R, Robertson V, Ssali F, Spyer M, Pillay D, Yirrell D, Kaleebu P; DART Virology Group and Trial Team. Gilks CF, et al. Among authors: kaleebu p. Antivir Ther. 2012;17(7):1363-73. doi: 10.3851/IMP2253. Epub 2012 Jul 19. Antivir Ther. 2012. PMID: 22814125 Clinical Trial.
A single CD4 test with 250 cells/mm3 threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria.
Gilks CF, Walker AS, Munderi P, Kityo C, Reid A, Katabira E, Goodall RL, Grosskurth H, Mugyenyi P, Hakim J, Gibb DM; DART Virology Group and Trial Team. Gilks CF, et al. PLoS One. 2013;8(2):e57580. doi: 10.1371/journal.pone.0057580. Epub 2013 Feb 21. PLoS One. 2013. PMID: 23437399 Free PMC article. Clinical Trial.
Immunogenicity of ALVAC-HIV vCP1521 in infants of HIV-1-infected women in Uganda (HPTN 027): the first pediatric HIV vaccine trial in Africa.
Kaleebu P, Njai HF, Wang L, Jones N, Ssewanyana I, Richardson P, Kintu K, Emel L, Musoke P, Fowler MG, Ou SS, Jackson JB, Guay L, Andrew P, Baglyos L, Cao H; HPTN 027 protocol team. Kaleebu P, et al. J Acquir Immune Defic Syndr. 2014 Mar 1;65(3):268-77. doi: 10.1097/01.qai.0000435600.65845.31. J Acquir Immune Defic Syndr. 2014. PMID: 24091694 Free PMC article. Clinical Trial.
399 results